Company: BIAF
Filing Date: 2025-10-08
Form Type: PRE 14A
Source: 0001493152-25-017460
Chunk: 32

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-10-08
Form: PRE 14A
Chunk 32
---
 
 of certain anti-dilution provisions of our common stock purchase warrants issued in connection with our private placement offering      
 that closed on August 14, 2025, that may be equal to or exceed 20% of our Common Stock outstanding before such offering (the “Warrant   
 Anti-Dilution Proposal”).                                                                                                               |

<div align='center'>FOR ☐ AGAINST ☐ ABSTAIN ☐</div>

| 3. | Proposal to consider and                                                                                                                 
 approve, pursuant to Nasdaq listing rules, the issuance of up to an aggregate of 131,884 shares of our Common Stock upon the triggering  
 of certain anti-dilution provisions of our Series B Convertible Preferred Stock issued in connection with our private placement offering 
 that closed on August 14, 2025, that may be equal to or exceed 20% of our Common Stock outstanding before such offering (the “Series     
 B Anti-Dilution Proposal”).                                                                                                              |

<div align='center'>FOR☐ AGAINST☐ ABSTAIN☐</div>

| 4. | Proposal to approve an                                                                                   
 amendment to the 2024 Equity Incentive Plan (the “2024 Plan”) to increase the number of shares of Common 
 Stock reserved for issuance thereunder to 750,000 shares from 66,666 shares (the “Plan Amendment”)       |

<div align='center'>FOR☐ AGAINST☐ ABSTAIN☐</div>

| 5. | Proposal to consider and                                                                                                              
 approve an adjournment of the Special Meeting to a later date, if necessary or appropriate, to permit further solicitation and vote   
 of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Warrant Exercise, 
 the Warrant Anti-Dilution Adjustment Proposal, the Series B Anti-Dilution Adjustment Proposal and/or the Plan Amendment Proposal      
 (the “Adjournment Proposal”).                                                                                                         |

<div align='center'>FOR☐ AGAINST☐ ABSTAIN☐</div>

In their discretion, the Proxies are authorized to vote upon such other matters as may properly come before the meeting or any adjournment thereof. Any of the Proxies, or their respective substitutes, who shall be present and acting at the Special Meeting shall have and may exercise all the powers hereby granted.

The undersigned acknowledges receipt of our Notice of Special Meeting of Stockholders and the Proxy Statement related thereto.

Please sign exactly as your